Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Lundbeck chair hits exit
H. Lundbeck's chairman excised himself from the company picture on Friday. Previously, Flemming Lindeløv had said he'd leave after the company's annual meeting in April, but he decided to leave early "to restore some calm." Perhaps in parting insult, Lundbeck shares rose on the news.
Lundbeck is squeezed on all sides--two of its in-development drugs failed late-stage trials this year, its patent on the top-selling antidepressant Lexapro expires in 2012, and it has yet to find a replacement drug. The company's plans to ramp up U.S. sales with a domestic sales force had to be postponed as well. Lindeløv will be replaced by board member Per Wold-Olsen, named previously as the chairman's successor.
- see this release
- read the AFX report
Related Articles:
Merck, Lundbeck end gaboxadol development. Report
Teva, H. Lundbeck stop work on oral Copaxone. Report
Lundbeck's shares plunge as drug flunks Phase III. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
